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Abstract 
Background: Weight loss is a cardinal symptom of oesophageal cancer and is often 
continued after surgery. High body mass index (BMI) is a strong risk factor for oesophageal 
adenocarcinoma. This study aimed to assess the impact of pre- and post-operative weight 
loss and BMI on long-term mortality after resection for oesophageal cancer. 
Methods: This prospective and nationwide cohort study included 390 patients, operated on 
for oesophageal cancer in Sweden in 2001-2005 with follow-up until 2016, who responded 
to a questionnaire on weight history 6 months after surgery. Multivariable Cox proportional 
hazard models provided hazard ratios (HRs) and 95% confidence intervals (95% CIs) of 
mortality while adjusting for several prognostic factors, including tumour stage.  
Results: Compared to weight stable patients, pre-surgery weight loss indicated increased 
HRs of overall all-cause mortality (HR=1.32, 95% CI 0.94-1.86) and disease-specific mortality 
(HR=1.36, 95% CI 0.93-1.98). Patients with >20% weight loss post-surgery had worse overall 
all-cause mortality (HR=1.71, 95% CI 1.01-2.88) and disease-specific mortality (HR=2.20, 95% 
CI 1.24-3.89). Compared to patients with normal BMI, decreased HRs were indicated for 
patients who were obese at the time of surgery (overall all-cause mortality HR 0.87 95% CI, 
0.58-1.31 and disease-specific mortality HR=0.89, 95% CI 0.57-1.40), while patients with BMI 
≤19.9 at 6 months post-surgery had increased all-cause mortality (HR=1.41, 95% CI 1.03-
1.95) and disease-specific mortality (HR=1.55, 95% CI 1.09-2.21).  
Conclusion: Post-operative weight loss and low BMI at 6 months post-surgery are 
independent markers of poor prognosis in patients who undergo surgery for oesophageal 
cancer. 
Keywords  
Oesophageal neoplasm; weight change; BMI; survival; mortality.
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INTRODUCTION 
Oesophageal carcinoma is the sixth leading cause of cancer-related mortality and the eighth 
most common cancer worldwide[1]. The overall 5-year survival rates are poor (<20%)[2] and 
the incidence of adenocarcinoma of the oesophagus is increasing rapidly[3]. High body mass 
index (BMI) is a well-recognised risk factor for adenocarcinoma of the oesophagus[4, 5]. 
Weight loss is a common (57-83%) presenting symptom of oesophageal cancer[6, 7]. 
Dysphagia, reduced oral intake, and altered nutrient metabolism associated with systemic 
inflammation induced by the tumour, can all contribute to this weight loss and 
malnutrition[6-8]. Surgery is the mainstay of curative treatment for patients diagnosed with 
locally advanced oesophageal cancer[9]. Malnutrition is associated with increased post-
operative morbidity and mortality after gastrointestinal surgery[10-12]. Some research 
indicates that pre-operative weight loss of >10% is associated with reduced overall 5-year 
survival after surgery for oesophageal cancer[13]. Continued weight loss and malnutrition 
are also common after surgery; post-surgery weight loss is seen in most patients, and is 
often profound and long-lasting[14, 15]. However, the impact of post-surgery weight loss on 
long-term survival has not been explored. The aim of this study was to assess the impact of 
pre- and post-operative weight loss and BMI on long-term survival after resection for 
oesophageal cancer.  
 
PATIENTS AND METHODS 
Design 
This was a prospective nationwide cohort study in Sweden, which builds on a long-lasting 
and all-encompassing research network of hospital departments and clinicians with an 
interest in oesophageal cancer established in the 1990s[16]. During the period 2001-2005, 
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90% of all surgically treated patients with oesophageal cancer in Sweden were included and 
the participants were followed up regularly post-operatively until February 2016. The 
principles and organisation of the nationwide data collection have been described 
elsewhere. The ethics committee at the Karolinska University Hospital, Karolinska Institutet, 
Sweden, approved the study; reference numbers: 01-064, date: 2001-02-05; 01-340, date: 
2005-12-29; 05/1491-32, date: 2005-12-29. Data regarding patient and tumour 
characteristics, hospital stay, surgery and complications were collected prospectively 
through continuous manual scrutiny of medical records. An extensive study protocol was 
completed by the study researchers for each patient, ensuring uniformity. Tumour stage 
was classified according to the International Union Against Cancer[17]. Mortality was 
determined by linkage to the 100% complete Swedish Register of the Total Population[18]. 
Data on weight changes were collected through written study-specific questionnaires 
assessing height and average weight as adults, weight just before operation, and weight at 
6 months after surgery[15]. Patients who responded to this questionnaire were eligible for 
this study. 
 
Exposures 
The study exposures were weight changes and BMI at defined time points in relation to 
surgery. Weight changes were evaluated in three categories: 1) between the average weight 
as an adult and weight at time of operation (‘Pre-operative weight change’); 2) between the 
time of surgery and 6 months following surgery (‘Post-operative weight change’); and 3) 
between the average weight as an adult and weight at 6 months after surgery (‘Pre-
operative to post-operative weight change’). Weight changes were categorised into four 
groups: 1) Weight gain or stable weight (+/-1.0%); 2) 1.1-10.0% weight loss; 3) 10.1-20.0% 
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weight loss; and 4) >20.0% weight loss. BMI (body weight in kilograms (kg) divided by the 
square of the body height in metres (m) [kg/m
2
]) was assessed at two time points: 1) at 
operation and 2) at 6 months post-surgery. BMI was categorised into four groups: ≤19.9 
(‘low’), 2) 20.0-24.9 (‘normal’), 3) 25.0-29.9 (‘overweight’), and 4) ≥30.0 (‘obesity’). 
 
Outcomes 
All-cause and disease-specific mortality was measured in days after surgery and assessed as 
6 months to end of study period (February 2016) and 6 months to 5 years. The follow-up 
from 6 months was because patients had to have survived for at least 6 months after their 
surgery to respond to the weight history questionnaires. All-cause mortality was defined as 
death from any cause during follow-up in the Swedish Causes of Death Registry[18]. 
Disease-specific mortality was defined as a death where oesophageal cancer was recorded 
as a cause of death during follow-up in the Causes of Death Registry[18]. 
 
Statistical analysis 
Kaplan Meyer survival curves were plotted and compared with the log rank test. Cox 
proportional hazard models were calculated to assess the hazard ratios (HRs) and 95% 
confidence intervals (CIs) of mortality associated with weight change and BMI. All HRs were 
adjusted for the following nine potential confounding factors: 1) age (continuous variable), 
2) sex (male or female), 3) comorbidity (categorised into 0, 1 or ≥2 according to the Charlson 
Index Scoring System)[19], 4) neoadjuvant therapy (yes or no), 5) tumour stage (0-I, II, III or 
IV), 6) placement of a feeding jejununostomy (yes or no), 7) surgical approach 
(oesophagectomy, extended total gastrectomy or oesophagogastrectomy), 8) histological 
type of tumour (adenocarcinoma or squamous-cell carcinoma), and 9) education (≤9, 10-12, 
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or >12 years of formal education). Additionally, the HRs evaluating post-operative weight 
change were further adjusted for pre-operative weight change, the HRs of BMI at operation 
were further adjusted for pre-operative weight change, and the HRs of BMI at 6 months 
were further adjusted for pre to post-operative weight change. Pre-operative, post-
operative and pre to post-operative (total) weight changes were categorised into weight 
gain or stable weight [+/-1%]; 1.1-10% weight loss; 10.1-20.0% weight loss; and >20.0% 
weight loss). Trend tests were performed to assess any linear trends in weight changes with 
respect to the study outcome using contrasts.  
 
Results 
Patients 
Of the entire cohort including 616 patients, 506 survived for at least 6 months and were 
thus eligible for this study. Among these, 402 answered the questionnaire about height and 
weight (79.4% response rate). Out of 402 patients 12 patients were removed due to missing 
information on weight loss or confounders. The remaining 390 patients were included in the 
present study. Characteristics of the study participants are presented in Table 1. There were 
more men (80.8%) than women, the average age was 65.6 years, and most patients had no 
comorbidity (57.7%). Tumour stage III (40.3%) was more common than other stages, and 
adenocarcinoma was the most common histological tumour type (75.9%). Few patients 
(6.4%) had received neoadjuvant therapy, a majority underwent oesophagectomy (79.7%) 
with clear resection margins (91.0%), and a feeding jejunostomy was inserted in 44.6% of 
patients (Table 1).  
 
Pre-operative weight loss and risk of mortality 
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As presented in Table 2, a majority (56.9%) of patients experienced weight loss before 
surgery. Pre-operative weight loss indicated increased point HRs of mortality, but these 
were not statistically significant (Table 2). The highest HR was found for disease-specific 
overall mortality among patients who had lost 10.1-20% of their weight before surgery (HR 
1.36, 95% CI 0.93-1.98). No clear trends with increased weight loss were found (Table 2).  
 
Post-operative weight loss and risk of mortality 
A large proportion of patients lost weight after surgery (86.9%) (Table 2). Patients with 
weight loss of >20% had an increased mortality compared to patients who were weight 
stable (all-cause overall mortality HR 1.71, 95% CI 1.01-2.88; disease-specific 5-year 
mortality HR 2.00, 95% CI 1.12-3.57; and disease-specific overall mortality HR 2.20, 95% CI 
1.24-3.89). There were statistically significant trends towards increased disease-specific  
mortality in patients who lost weight (Table 2). 
 
Pre-operative to post-operative weight change and risk of mortality 
Most patients (95.5%) lost weight from before the disease to 6 months after surgery, the 
majority of whom (74.5%) lost >10%. Patients with weight loss of >20% had strongly 
increased HR of mortality compared to patients who were weight stable (disease-specific 5-
year mortality HR 2.83, 95% CI 1.00-8.02; disease-specific overall mortality HR 3.29, 95% CI 
1.17-9.29) (Table 2). There was also a statistically significant trend towards increased overall 
disease-specific mortality for patients who lost weight (p=0.03).  
 
BMI at operation and risk of mortality 
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The largest group of patients (40.6%) had a BMI within the normal range (20-24.9) at the 
time of surgery. A low BMI of ≤19.9, was seen in 10.3% of patients. Compared to patients 
with a normal BMI, there was no increased HRs of mortality in patients who were 
underweight, overweight or obese (Table 3). However, there were statistically non-
significantly decreased HRs for the BMI ≥30 category (Table 3). 
A sub analysis was undertaken to assess mortality in patients with a high pre-operative BMI 
(BMI ≥25) and high post-operative weight loss (≥20%) compared to patients with a pre-
operative BMI <25 and <20% post-operative weight loss. Having a high pre-operative BMI 
and high post-operative weight loss indicated increased point HRs of mortality (disease-
specific 5-year mortality HR 1.20 95% CI 0.79-1.81; disease-specific overall mortality HR 1.38 
95% CI 0.92-2.07), but these were not statistically significant.  
 
BMI at 6 months after surgery and risk of mortality 
The proportions of patients with a normal BMI and with a BMI ≤19.9 at 6 months after 
surgery were 53.7% and 25.3%, respectively. Conversely, the proportions of patients within 
the overweight and obese categories were reduced to 18.9% and 2.1%, respectively. 
Patients with a low BMI (≤19.9) had higher all-cause and disease-specific HRs of mortality 
compared to patients with a normal BMI (Table 3). Compared to patients in the normal 
range of BMI, those who had a BMI of ≤19.9 had a HR of disease-specific 5-year mortality of 
1.66 (95% CI 1.16-2.38). The HRs for the BMI ≥30 category were non-significantly decreased 
(Table 3). 
 
A sensitivity analysis excluding patients (n=35, 9.0%) with non-radical resection margins 
(R1/2) did not change the HRs for any of the exposures or outcomes (data not shown). 
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Discussion 
In this study, weight loss after surgery and low BMI (≤19.9) at 6 months post-surgery were 
independent and statistically significant poor prognostic indicators in patients who 
underwent surgery for oesophageal cancer, while pre-operative weight loss of >10% might 
also increase mortality. Having a BMI ≥30 before or after surgery may be a good prognostic 
factor. 
 
Strengths of this study include its prospective and population-based design with inclusion of 
unselected patients undergoing cancer surgery, with high questionnaire response rate. 
Other strengths are the large sample size, the high national coverage, the complete and long 
follow-up and the adjustment for several potential confounding factors. The detailed and 
prospective data collection and the objective manual review of each case record including 
evaluation of internal validity ensured high validity of the collected data. The self-reported 
data on weight and height is a potential weakness. However, the weight of these patients is 
typically objectively measured repeatedly from before surgery and at clinical follow-ups, 
making it likely that the reported measures were in fact accurate in most patients.   Patient-
reported height, weight and weight change history have been shown to be reliable[20, 21].   
A study from the same cohort validated self-reporting of weight [20], showing a correlation 
coefficient of 0.77, indicating good correlation. Another limitation is that patients who did 
not survive 6 months after surgery were not included. This may have mitigated the impact 
of mortality associated with post-operative complications on survival. However, it is unlikely 
that the associations found in this study would have been weaker if early post-operative 
deaths were also included, but rather the opposite. Finally, the lack of details around pre-
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
operative weight loss, in terms of the time frame and whether the weight loss was 
unintentional or not, may have affected the results of the pre-operative and total weight 
changes analysis.  
Malnutrition is a common condition after surgery for oesophageal cancer[15, 20, 22]. Yet, 
the impact of post-operative malnutrition on survival has been poorly studied. The present 
study showed a strong and dose-response association between increasing weight loss and 
increased mortality. In a study of 1-year survivors (n=205) after transthoracic 
oesophagectomy for cancer, a ≥10% weight loss had an independent negative prognostic 
impact on disease-free survival[23]. Previous studies which found reduced survival 
associated with weight loss attributed this to those patients who lost weight receiving less 
chemotherapy[24, 25]. However, the majority of patients in the present cohort (93.6%) did 
not receive perioperative oncological treatment. The results were adjusted for tumour stage 
to assess if the association between weight loss and mortality was a reflection of a more 
advanced tumour; however this was not the case. 
 
Malnutrition is associated with compromised immunity[26]. The immune system is the 
body’s primary defence against cancer cells[27]. Tumours are recognised by the immune 
system and their development can be stopped or controlled long term through a process 
known as immunosurveillance[28]. Therefore, this could be a factor in earlier disease 
recurrence in patients who lose weight. Also, the survival advantage seen in the patients 
who are obese might be associated with their greater nutritional reserve.  
 
The HRs of this study indicated that pre-operative weight loss >10% increased the mortality 
independent of other factors, although no statistically significant association was shown. 
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The aforementioned study weaknesses in relation to the exclusion of patients who did not 
survive 6 months after surgery and the lack of detail around the weight loss could have 
diluted these results. Several other studies have reported that pre-operative weight loss of 
>10% increases the risk of mortality after oesophageal cancer surgery[13, 29, 30]. Another 
study found that >2% pre-operative weight loss was an independent predictor of reduced 5-
year survival in patients after oesophagectomy[31]. Weight changes in the current study 
were classified into 4 categories to investigate if there were any differences in the impact on 
survival of weight loss at various rates with the aim of providing insight to aid clinical 
decision-making.  
 
Our study demonstrated that being obese at the time of surgery and at 6 months post-
surgery is a possible good independent prognostic factor, although this was not statistically 
significant. A survival benefit with having a high BMI has been reported in some studies 
examining pre-surgery BMI and survival in oesophageal cancer[32, 33], whilst others have 
found the effect equivocal[34, 35]. Comparison however with other literature was difficult 
due to the differing classifications of BMI used, often dichotomous classifications of </> 30 
or </> 25 [33-35]. We used the World Health Organisation’s (WHO) classification of BMI[36] 
with the exception of the underweight category, which was classified as ≤19.9 instead of 
<18.5. Having a BMI <20 is considered to be malnourished if accompanied with 5% 
unintentional weight loss[37] which was the rationale for using the cut off ≤19.9.  
 
It would seem clear that interventions to minimise weight loss before and after surgery have 
the potential to improve survival. Jejunostomy feeding tubes are often used to feed patients 
after surgical resection for oesophageal cancer, with some patients continuing jejunostomy 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
12 
 
feeding at home[38]. A study from our group indicated a reduced risk of weight loss in the 
patients who had a jejunostomy[39]. Therefore, presence of jejunostomy tubes was 
adjusted for in the current study; this was not found to be a confounder or mediator of the 
associations reported. Jejunostomy feeding tubes are not without risk of serious 
complications[40]. With an increasing focus on survivorship, and developments in symptom 
management, jejunostomy feeding tubes may not be the optimal intervention for many 
patients. Further research is needed to substantiate the benefits of jejunostomy feeding 
over intensive dietary counselling and support along with symptom management, and to 
determine optimum patient selection. Indeed jejunostomy feeding would need to be 
considered as part of a multimodal approach to counteract weight loss rather than in 
isolation, as it is becoming increasing evident that loss of muscle mass, or sarcopenia, is 
likely to be more of a confounding factor on survival than simply weight loss.  
 
Sarcopenia is prevalent in patients with oesophago-gastric cancer before surgery and has 
been shown to be associated with chemotherapy dose limiting toxicity and with poorer 
survival[41, 42, 43, 44, 45]. The patients in this study with postoperative weight loss and low 
BMI (≤19.9) may be considered potentially sarcopenic, contributing to their higher risk of 
mortality.   
 
Given the complexity of factors which affect nutritional status, integrated multimodal 
approaches to intervention would seem appropriate. With the prevalence of malnutrition 
increasing from diagnosis into survivorship and considering the impact this has on 
outcomes, it would seem paramount that interventions should be implemented with the 
aim of prevention rather than reversal, in order to prevent weight loss surpassing that level 
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beyond which the detriment occurs. Further research evaluating the impact of surgery on 
body composition and its implications on survival would be valuable. Interventions which 
may mitigate the impact of treatment on skeletal muscle mass, such as physical activity and 
nutrition, should be a key consideration of any prehabilitation and rehabilitation programs.  
 
In conclusion, this nationwide population-based cohort study with adjustment for known 
prognostic factors indicates that post-operative weight loss and low BMI (≤19.9) at 6 months 
post-surgery are independent poor prognostic indicators in patients who undergo surgery 
for oesophageal cancer. Pre-operative weight loss >10% was shown to be potentially 
hazardous, while being obese before and after surgery may infer a survival benefit. Early 
and timely interventions to prevent or minimise malnutrition in this group of patients has 
the potential to improve prognosis.  
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Table 1: Characteristics of patients who underwent surgery for 
oesophageal cancer. 
Age (mean, in years) 65.6 
 Number (%) of patients  
Gender    
Male 315 (80.8) 
Female 75 (19.2)  
Education    
Nine-year compulsory 181 (46.4) 
Upper Secondary 152 (39) 
Higher Education/Degree 57 (14.6) 
Charlson comorbidity score   
0 225 (57.7) 
1 95 (24.4) 
≥2 70 (17.9) 
Tumour stage (post-operative)   
0-I 82 (21.0) 
II 119 (30.5) 
III 157 (40.3) 
IV 32 (8.2) 
Tumour histology    
Adenocarcinoma and dysplasia 296 (75.9) 
Squamous cell carcinoma 94 (24.1) 
Neoadjuvant chemotherapy received   
Yes 25 (6.4) 
No 365 (93.6) 
Surgical approach   
Oesophagectomy 311 (79.7) 
Extended total gastrectomy 40 (10.3) 
Oesophagogastrectomy 39 (10.0) 
Resection margin status    
Radical (R0) 355 (91.0) 
Non-radical (R1/2) 35 (9.0) 
Placement of a feeding jejunostomy    
Yes 174 (44.6) 
No 216 (55.4) 
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Table 2: Perioperative weight changes in patients with oesophageal cancer and risk of mortality, presented as hazard ratio (HR) with 95% confidence interval (CI)
 a
 
   All-cause mortality Disease-specific mortality 
    Within 5 years of surgery Overall  Within 5 years of surgery  Overall 
Pre-operative weight 
change Number (%)
b
 HR 95% CI 
P for 
trend HR 95% CI 
P for 
trend HR 95% CI 
P for 
trend HR 95% CI 
P for 
trend 
Stable/gain (+/-1%) 153 (43.1) 1.00 reference  1.00 reference  1.00 reference  1.00 reference  
1.1-10% 116 (32.7) 0.85 0.62-1.17  0.84 0.63-1.14  0.79 0.56-1.12  0.79 0.57-1.11  
10.1-20% 57 (16.0) 1.26 0.87-1.81  1.32 0.94-1.86  1.33 0.91-1.97  1.36 0.93-1.98  
>20% 29 (8.2) 1.19 0.74-1.92 0.23 1.10 0.69-1.76 0.31 1.18 0.72-1.94 0.20 1.04 0.64-1.69 0.39 
Post-operative weight 
change at 6 months  Number (%)
b
 HR 95% CI 
P for 
trend HR 95% CI 
P for 
trend HR 95% CI 
P for 
trend HR 95% CI 
P for 
trend 
Stable/gain (+/-1%) 50 (13.1) 1.00 reference  1.00 reference  1.00 reference  1.00 reference  
1.1-10% 97 (25.4) 1.20 0.75-1.93  1.28 0.82-2.00  1.28 0.78-2.11  1.45 0.89-2.37  
10.1-20% 162 (42.4) 1.24 0.77-1.99  1.21 0.78-1.90  1.35 0.82-2.22  1.29 0.80-2.09  
>20% 73 (19.1) 1.70 0.98-2.95 0.06 1.71 1.01-2.88 0.06 2.00 1.12-3.57 0.02 2.20 1.24-3.89 0.01 
Pre-operative to post-
operative weight change 
(total) Number (%)
b
 HR 95% CI 
P for 
trend HR 95% CI 
P for 
trend HR 95% CI 
P for 
trend HR 95% CI 
P for 
trend 
Stable/gain (+/-1%) 16 (4.5) 1.00 reference  1.00 reference  1.00 reference  1.00 reference  
1.1-10% 74 (21.0) 1.59 0.66-3.79  1.55 0.72-3.34  1.90 0.66-5.50  2.07 0.72-5.94  
10.1-20% 168 (47.6) 1.31 0.57-3.04  1.31 0.63-2.74  1.58 0.57-4.44  1.87 0.68-5.21  
>20% 95 (26.9) 2.10 0.90-4.92 0.12 2.03 0.96-4.28 0.09 2.83 1.00-8.02 0.07 3.29 1.17-9.29 0.03 
a
Results adjusted for age, sex, education, co morbidity, tumour stage, tumour histology, pre-operative weight change in the analysis of post-operative weight change, 
neoadjuvant chemotherapy received, surgical approach and presence of a jejunostomy.  
b
Number of patients not adding up to 390 patients represent missing data.  
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Table 3: Perioperative body mass index (BMI) in patients having surgery for oesophageal cancer and risk of 
mortality, presented as hazard ratio (HR) with 95% confidence interval (CI)
 a
 
    All-cause mortality Disease-specific mortality 
    
 Within 5 years 
of surgery  Overall  
 Within 5 years 
of surgery  Overall  
BMI at 
operation  
Number 
(%)
b
 
HR  95% CI HR 95% CI HR 95% CI HR 95% CI 
≤19.9 39 (10.3) 1.05 0.64-1.72 1.01  0.63-1.64 1.02 0.60-1.74 1.07 0.62-1.85 
20-24.9 153 (40.6) 1.00 reference 1.00 reference 1.00 reference 1.00 reference 
25-29.9 121 (32.1) 1.15 0.82-1.61 1.15 0.84-1.58 1.04 0.72-1.50 1.08 0.76-1.53 
≥30 64 (17) 0.83 0.53-1.31 0.87 0.58-1.31 0.80 0.50-1.27 0.89 0.57-1.40 
BMI at 6 
months post-
surgery 
Number 
(%)
b
 
HR  95% CI HR 95% CI HR 95% CI HR 95% CI 
≤19.9 95 (25.3) 1.51 1.08-2.11 1.41 1.03-1.95 1.66 1.16-2.38 1.55 1.09-2.21 
20-24.9 202 (53.7) 1.00 reference 1.00 reference 1.00 reference 1.00 reference 
25-29.9 71 (18.9) 0.90 0.60-1.33 0.79 0.54-1.14 0.93 0.61-1.40 0.87 0.58-1.29 
≥30 8 (2.1) 0.73 0.25-2.09 0.79 0.31-2.04 0.73 0.25-2.11 0.57 0.20-1.67 
a
Adjusted for age, sex, education, co morbidity, tumour stage, tumour histology, preoperative weight change 
in the analysis of BMI at operation, pre to post-operative weight change in the analysis of BMI at 6 months, 
neoadjuvant chemotherapy received, surgical approach and presence of a jejunostomy. 
b
Number of patients not adding up to 390 patients represent missing data. 
 
 
 
 
